title: Benefits of photopheresis in the treatment of heart transplant patients with multiple/refractory rejection.
authors.affiliation: Department of Pediatrics, University of Padua, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Dall'Amico
authors.forename: G
authors.initials: G
authors.lastname: Montini
authors.forename: L
authors.initials: L
authors.lastname: Murer
authors.forename: B
authors.initials: B
authors.lastname: Andreetta
authors.forename: V
authors.initials: V
authors.lastname: Tursi
authors.forename: G
authors.initials: G
authors.lastname: Feltrin
authors.forename: G
authors.initials: G
authors.lastname: Guzzi
authors.forename: A
authors.initials: A
authors.lastname: Angelini
authors.forename: G
authors.initials: G
authors.lastname: Zacchello
authors.forename: U
authors.initials: U
authors.lastname: Livi
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001707:Biopsy, Needle; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000473:pathology / Q000628:therapy*; D016027:Heart Transplantation / Q000276:immunology / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D017893:Photopheresis; D012008:Recurrence; D013997:Time Factors
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D008775:Methylprednisolone; D008727:Methotrexate